Christina Damoulari
A5056440685- COVID-19 Clinical Research Studies
- Immune responses and vaccinations
- Inflammasome and immune disorders
- COVID-19 Impact on Reproduction
- Sepsis Diagnosis and Treatment
- Long-Term Effects of COVID-19
- Sexual Differentiation and Disorders
- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- Pneumonia and Respiratory Infections
- Hepatocellular Carcinoma Treatment and Prognosis
- Economic and Financial Impacts of Cancer
- Fungal Infections and Studies
- Dermatological and COVID-19 studies
- Whipple's Disease and Interleukins
- Galectins and Cancer Biology
- Female Genital Mutilation/Cutting Issues
- Hidradenitis Suppurativa and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Microscopic Colitis
- Colorectal and Anal Carcinomas
- Antifungal resistance and susceptibility
- Sulfur Compounds in Biology
- Reproductive Health and Technologies
- Streptococcal Infections and Treatments
National and Kapodistrian University of Athens
2020-2024
University General Hospital Attikon
2020-2022
Biomedical Research Foundation of the Academy of Athens
2022
University of Patras
2002-2015
Abstract Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative increased risk progression coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE double-blind, randomized controlled trial evaluated the efficacy and safety anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at progressing failure as identified by plasma suPAR ≥6 ng ml −1 , 85.9% ( n = 510) whom were receiving dexamethasone. At day 28, adjusted...
In a recent study of our group with the acronym ACTIVATE, Bacillus Calmete-Guérin (BCG) vaccination reduced occurrence new infections compared to placebo in elderly. Most benefit was found for respiratory infections. The ACTIVATE-2 launched assess efficacy BCG against coronavirus disease 2019 (COVID-19). this multicenter, double-blind trial, 301 volunteers aged 50 years or older were randomized (1:1) be vaccinated placebo. trial end points incidence COVID-19 and presence anti–severe acute...
The pneumonia of COVID-19 illness has often a subtle initial presentation making mandatory the use biomarkers for evaluation severity and prediction final patient disposition. We evaluated hydrogen sulfide (H2S) outcome pneumonia.We studied 74 patients with COVID-19. Clinical data were collected, survival predictors calculated. Blood was collected within 24 h after admission (day 1) on day 7. H2S measured in sera by monobromobimane derivation followed high-performance liquid chromatography...
SUMMARY BCG vaccination induces heterologous protection against respiratory tract infections, and in children improves survival independently of tuberculosis prevention. The phase III ACTIVATE-2 study assessed whether could also protect COVID19 the elderly. In this double-blind, randomized trial, elderly Greek patients were (1:1) to receive either revaccination or placebo at hospital discharge, followed by 6 months observation for incidence infection. resulted 68% risk reduction total...
The isolation of a pan-echinocandin-resistant Candida parapsilosis strain (anidulafungin, caspofungin, micafungin and rezafungin EUCAST MICs > 8 mg/L) from urine patient following prolonged exposure to echinocandins (38 days followed by 16 anidulafungin) is described. isolate harbored the novel alteration F652S in hotspot 1 region fks1. Isogenic C. bloodstream isolates collected up 1.5 months earlier same were susceptible caspofungin 1−2, mg/L, respectively) contained wild-type FKS1...
Introduction Until recently, biologic therapy for hidradenitis suppurativa was limited to anti-tumor necrosis factor (TNF) blockade with adalimumab (ADA). However, not all patients respond treatment ADA. This highlighted the need more therapeutic options. Interleukin (IL)-17/T-helper17 (Th17) axis may play an important role in pathophysiology of HS. Recently, IL-17A inhibitor secukinumab, which targets specifically and prevents it from interacting IL-17 receptor, has been FDA-approved
The anti-inflammatory effect of macrolides prompted the study oral clarithromycin in moderate COVID-19.An open-label non-randomized trial 90 patients with COVID-19 severity was conducted between May and October 2020. primary endpoint defined at end treatment (EOT) as no need for hospital re-admission progression into lower respiratory tract infection (LRTI) upper least 50% decrease symptoms score without severe failure (SRF) LRTI. Viral load, biomarkers, function mononuclear cells safety...
ABSTRACT Background In a previous open-label trial, early anakinra treatment guided by elevated soluble urokinase plasminogen activator receptor (suPAR) prevented progression of COVID-19 pneumonia into respiratory failure. Methods the SAVE-MORE multicenter 594 hospitalized patients with moderate and severe plasma suPAR 6 ng/ml or more receiving standard-of-care were 1:2 randomized to subcutaneous placebo 100 mg once daily for 10 days. The primary endpoint was overall clinical status 11-point...
ABSTRACT Background To study the efficacy of oral clarithromycin in moderate COVID-19. Methods An open-label non-randomized trial 90 patients with COVID-19 severity was conducted between May and October 2020. The primary endpoint defined at end-of-treatment (EOT) as no need for hospital re-admission progression into lower respiratory tract infection (LRTI) upper infection; least 50% decrease symptoms score without severe failure (SRF) LRTI. Viral load, biomarkers, function mononuclear cells,...
Abstract Early recognition of risk and start treatment may improve unfavorable outcome COVID-19. In the SAVE-MORE double-blind randomized trial, 594 patients with pneumonia without respiratory dysfunction at as defined by plasma suPAR (soluble urokinase plasminogen activator receptor) ≥ 6 ng/ml were 1:2 to subcutaneous placebo or 100 mg anakinra once daily for 10 days; 85.9% co-administered dexamethasone. After 28 days, anakinra-treated distributed lower strata 11-point World Health...
We studied whether progression of severe pneumonia into post-acute COVID-19 syndrome (PACS) is associated with long-term immune dysregulation. Patients known history during two different time periods and matched comparators were divided a discovery cohort (n=46, September-October 2020) validation (n=484, June-August 2021). Peripheral blood mononuclear cells (PBMCs) stimulated for cytokine production, patient-reported questionnaires lung function tests (LFTs) analyzed. Increased production...